tesamorelin hiv: Frequently asked questions

No. Tesamorelin HIV lipodystrophy treatment and ART regimen changes are independent decisions that do not require coordination. Switching from older protease inhibitors or NRTIs to newer integrase inhibitors may slow future VAT accumulation but will not reverse existing lipodystrophy, which is why continuing tesamorelin during and after the ART switch is appropriate. Discuss the timing with your infectious disease specialist, as some ART regimens may have mild pharmacokinetic interactions with GH signaling pathways, though no direct drug-drug interactions between tesamorelin and common ART agents have been documented in clinical trials. The combination of an integrase-based regimen plus tesamorelin represents the most evidence-based strategy for managing lipodystrophy while maintaining viral suppression.

Approximately 30% of patients are partial or non-responders to tesamorelin HIV lipodystrophy treatment, often due to severe baseline insulin resistance, low baseline IGF-1 levels indicating GH resistance, or genetic polymorphisms in GH receptor signaling. Request repeat imaging (CT or MRI) to measure actual VAT area. Waist circumference can be confounded by subcutaneous fat, bowel gas, or muscle mass, while imaging provides definitive quantification. If VAT has decreased by less than 10% despite documented adherence and adequate IGF-1 elevation, your provider may trial a dose increase to 3mg daily (off-label), add metformin to improve insulin sensitivity and potentiate lipolysis, or discontinue therapy and explore alternative strategies such as switching ART regimens or intensive metabolic management with an endocrinologist.

Resume your daily injections at the standard 2mg dose as soon as you remember. Do not double-dose to compensate for missed days. Missing 3-5 consecutive days will not immediately reverse VAT reduction, but gaps longer than one week may result in measurable reaccumulation of visceral fat. Growth hormone levels return to baseline within 48-72 hours of the last dose, so lipolytic activity ceases during the gap. If you miss more than 7 consecutive days, contact your prescribing physician to discuss whether re-initiation requires a brief titration period to minimize injection site reactions, though most patients tolerate immediate resumption at full dose.

Transient glucose elevation occurs in 10-15% of patients during the first 8-12 weeks of tesamorelin HIV lipodystrophy treatment, reflecting GH's counter-regulatory effects on insulin signaling. If your fasting glucose increases by 10-20 mg/dL but remains below 126 mg/dL (pre-diabetic threshold), continue therapy with weekly glucose monitoring. Levels often stabilize or normalize by week 12 as insulin sensitivity improves secondary to VAT reduction. If fasting glucose exceeds 126 mg/dL or HbA1c rises above 6.5%, your provider may reduce the dose to 1mg daily, add metformin to improve insulin sensitivity, or discontinue tesamorelin if hyperglycemia persists. Patients with baseline diabetes should have their oral hypoglycemic or insulin doses optimized before starting tesamorelin to minimize this risk.

Interruptions shorter than 2 weeks cause minimal setback. Resume at the same dose once medically cleared. Interruptions longer than 4 weeks reset the metabolic adaptation process: GH pulsatility drops, HSL activity declines, and you'll need to re-titrate through the initiation phase. If stopping for planned surgery, coordinate with your prescriber to time the interruption after the 26-week endpoint if possible, so you've achieved maximum VAT reduction before pausing.

Verify dosage accuracy and injection technique first. Reconstitution errors or subcutaneous technique failures are more common than true non-response. If dosing is correct, request IGF-1 testing: patients with baseline IGF-1 below 100 ng/mL often need 14–16 weeks to show measurable VAT reduction because the GH axis takes longer to restore. True non-responders (those showing zero VAT change at 16 weeks despite verified adherence) represent roughly 8–12% of patients and typically have pre-existing GH resistance unrelated to lipodystrophy.

This is the expected response pattern. Tesamorelin reduces visceral fat while preserving or slightly increasing lean mass via IGF-1's anabolic effects on muscle tissue. CT imaging would show VAT area reduction even if scale weight is unchanged. Weight stability with waist reduction is a positive outcome. It means the medication is working as intended, targeting pathological visceral fat without causing muscle wasting.

Egrifta SV may cause serious side effects, including:

Egrifta SV (tesamorelin) is an injectable prescription medicine used to reduce the excess stomach-area (abdominal) fat in HIV-infected adult patients with lipodystrophy. Egrifta SV is a growth hormone-releasing factor (GHRF). The long-term safety of Egrifta SV on the heart and blood vessels (cardiovascular) is not known. Egrifta SV is not for weight loss management. It is not known whether taking Egrifta SV helps improve how well you take (compliance with) antiretroviral medicines. It is not known if Egrifta SV is safe and effective in children.

Injection site reactions (erythema, pruritus, induration) occur in 35–40% of patients initially but typically resolve by week 4–6 as the immune system acclimates to the peptide. Persistent reactions beyond 8 weeks suggest either contaminated reconstitution technique or an allergic response to the peptide itself. Switch to a fresh box of vials stored correctly, ensure you're using sterile water (not bacteriostatic water, which contains benzyl alcohol that some patients react to), and confirm the needle gauge is 27G or finer. If reactions persist despite technique correction, discontinue and consult your prescriber. True peptide allergy is rare but prohibits further use.

Reassess three variables: injection technique, dietary carbohydrate intake, and baseline IGF-1 response. If IGF-1 hasn't increased by at least 50 ng/mL from baseline, the peptide isn't triggering sufficient GH release. This occurs in 10–15% of patients and suggests pituitary hyporesponsiveness that won't improve with higher doses. If IGF-1 has risen appropriately but VAT remains stable, the issue is energy balance: tesamorelin stimulates lipolysis, but if caloric intake (especially refined carbohydrates) drives de novo lipogenesis at an equal or greater rate, net VAT remains unchanged. Reducing daily carbohydrate intake to under 150g while maintaining the protocol typically restarts VAT reduction within 4–6 weeks.

No. Never double-dose tesamorelin. The peptide's mechanism depends on mimicking natural GH pulsatility, and a 4mg dose would create a supra-physiological spike that increases glucose intolerance risk without additional VAT reduction. If you miss a dose by fewer than 12 hours, administer it as soon as you remember and continue the regular schedule the next day. If more than 12 hours have passed, skip the missed dose entirely and resume at the usual time. Missing 2–3 doses per month reduces cumulative VAT reduction by approximately 8–12% at 26 weeks based on adherence subset analysis from the COSMIX trial.

Recheck fasting glucose and HbA1c within 2 weeks. If fasting glucose remains >126 mg/dL on repeat testing or HbA1c increases by >0.5% from baseline, discontinue tesamorelin and consult your prescribing physician. The glucose elevation is a direct pharmacological effect of increased IGF-1 impairing peripheral insulin sensitivity. Dose reduction does not mitigate this risk. Most patients see glucose normalize within 4–8 weeks of stopping. If VAT reduction is clinically necessary, an endocrinologist may recommend metformin or other insulin sensitizers before attempting to restart at a lower frequency (e.g., 5 days per week instead of 7).

No. Administer the missed dose as soon as you remember within the same 24-hour period, then resume your regular schedule the following evening. If more than 24 hours have passed, skip the missed dose entirely and continue with the next scheduled injection. Doubling the dose disrupts the pulsatile GH rhythm tesamorelin is designed to mimic and increases the risk of hyperglycemia, joint pain, and fluid retention. Missing occasional doses reduces cumulative VAT reduction but does not negate prior progress. Consistency over weeks matters more than perfection on individual days.

First, verify adherence: are you injecting nightly without missed doses? Second, confirm storage integrity. Has the medication been maintained at 2–8°C continuously, including during reconstitution and between pharmacy delivery and home refrigeration? Third, request waist circumference measurement and DEXA scan or CT imaging to quantify VAT objectively. Patient perception of abdominal fat does not correlate reliably with visceral adiposity. If all of the above are confirmed and imaging shows <5% VAT reduction at 12 weeks, you may be a non-responder (seen in approximately 15–20% of patients). Possible mechanisms include genetic variations in GHRH receptor density, concurrent medications that suppress GH secretion (e.g., glucocorticoids), or advanced hepatic steatosis blunting GH responsiveness.